Therapeutic Drug Monitoring of Anti-infective Drugs: Implementation Strategies for 3 Different Scenarios

被引:12
作者
Kim, Hannah Yejin [1 ,2 ,3 ]
Byashalira, Kenneth C. [4 ]
Heysell, Scott K. [5 ]
Martson, Anne-Grete [6 ]
Mpagama, Stellah G. [4 ]
Rao, Prakruti [5 ]
Sturkenboom, Marieke G. G. [6 ]
Alffenaar, Jan-Willem C. [1 ,2 ,3 ]
机构
[1] Univ Sydney, Fac Med & Hlth, Sch Pharm, Pharm Bldg A15, Sydney, NSW 2006, Australia
[2] Univ Sydney, Westmead Hosp, Sydney, NSW, Australia
[3] Univ Sydney, Marie Bashir Inst Infect Dis, Sydney, NSW, Australia
[4] Kibongoto Infect Dis Hosp, Moshi, Tanzania
[5] Univ Virginia, Div Infect Dis & Int Hlth, Charlottesville, VA USA
[6] Univ Groningen, Univ Med Ctr Groningen, Dept Clin Pharm & Pharmacol, Groningen, Netherlands
基金
美国国家卫生研究院;
关键词
therapeutic drug monitoring; limited sampling; dosing software; saliva; DRIED BLOOD SPOTS; ANTITUBERCULOSIS DRUGS; LC-MS/MS; VANCOMYCIN; RIFAMPICIN; HIV; PHARMACOKINETICS; ANTIBIOTICS; GENTAMICIN; CHALLENGES;
D O I
10.1097/FTD.0000000000000936
中图分类号
R446 [实验室诊断]; R-33 [实验医学、医学实验];
学科分类号
1001 ;
摘要
Background: Therapeutic drug monitoring (TDM) supports personalized treatment. For successful implementation, TDM must have a turnaround time suited to the clinical needs of patients and their health care settings. Here, the authors share their views of how a TDM strategy can be tailored to specific settings and patient groups. Methods: The authors selected distinct scenarios for TDM: high-risk, complex, and/or critically ill patient population; outpatients; and settings with limited laboratory resources. In addition to the TDM scenario approach, they explored potential issues with the legal framework governing dose escalation. Results: The most important issues identified in the different scenarios are that critically ill patients require rapid turnaround time, outpatients require an easy sampling procedure for the sample matrix and sample collection times, settings with limited laboratory resources necessitate setting-specific analytic techniques, and all scenarios warrant a legal framework to capture the use of escalated dosages, ideally with the use of trackable dosing software. Conclusions: To benefit patients, TDM strategies need to be tailored to the intended population. Strategies can be adapted for rapid turnaround time for critically ill patients, convenient sampling for outpatients, and feasibility for those in settings with limited laboratory resources.
引用
收藏
页码:3 / 10
页数:8
相关论文
共 63 条
  • [1] Antimicrobial therapeutic drug monitoring in critically ill adult patients: a Position Paper#
    Abdul-Aziz, Mohd H.
    Alffenaar, Jan-Willem C.
    Bassetti, Matteo
    Bracht, Hendrik
    Dimopoulos, George
    Marriott, Deborah
    Neely, Michael N.
    Paiva, Jose-Artur
    Pea, Federico
    Sjovall, Fredrik
    Timsit, Jean F.
    Udy, Andrew A.
    Wicha, Sebastian G.
    Zeitlinger, Markus
    De Waele, Jan J.
    Roberts, Jason A.
    [J]. INTENSIVE CARE MEDICINE, 2020, 46 (06) : 1127 - 1153
  • [2] Therapeutic Drug Monitoring in Non-Tuberculosis Mycobacteria Infections
    Alffenaar, Jan-Willem
    Martson, Anne-Grete
    Heysell, Scott K.
    Cho, Jin-Gun
    Patanwala, Asad
    Burch, Gina
    Kim, Hannah Y.
    Sturkenboom, Marieke G. G.
    Byrne, Anthony
    Marriott, Debbie
    Sandaradura, Indy
    Tiberi, Simon
    Sintchencko, Vitali
    Srivastava, Shashikant
    Peloquin, Charles A.
    [J]. CLINICAL PHARMACOKINETICS, 2021, 60 (06) : 711 - 725
  • [3] A mobile microvolume UV/visible light spectrophotometer for the measurement of levofloxacin in saliva
    Alffenaar, Jan-Willem C.
    Jongedijk, Erwin M.
    van Winkel, Claudia A. J.
    Sariko, Margaretha
    Heysell, Scott K.
    Mpagama, Stellah
    Touw, Daan J.
    [J]. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2021, 76 (02) : 423 - 429
  • [4] Therapeutic Drug Monitoring: The Need for Practical Guidance
    Alffenaar, Jan-Willem C.
    Heysell, Scott K.
    Mpagama, Stellah G.
    [J]. CLINICAL INFECTIOUS DISEASES, 2019, 68 (06) : 1065 - 1066
  • [5] Therapeutic Drug Monitoring in Tuberculosis: Practical Application for Physicians
    Alffenaar, Jan-Willem C.
    Tiberi, Simon
    Verbeeck, Roger K.
    Heysell, Scott K.
    Grobusch, Martin P.
    [J]. CLINICAL INFECTIOUS DISEASES, 2017, 64 (01) : 104 - +
  • [6] [Anonymous], 2010, RETH MED DEC MAK AUS
  • [7] Australian Government Department of Health: Therapeutic Goods Administration, 2019, CONS REG SOFTW INCL
  • [8] The role of therapeutic drug monitoring in treatment of HIV infection
    Back, DJ
    Khoo, SH
    Gibbons, SE
    Merry, C
    [J]. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2001, 51 (04) : 301 - 308
  • [9] Combined Impact of Inflammation and Pharmacogenomic Variants on Voriconazole Trough Concentrations: A Meta-Analysis of Individual Data
    Bolcato, Lea
    Khouri, Charles
    Veringa, Anette
    Alffenaar, Jan Willem C.
    Yamada, Takahiro
    Naito, Takafumi
    Lamoureux, Fabien
    Fonrose, Xavier
    Stanke-Labesque, Francoise
    Gautier-Veyret, Elodie
    [J]. JOURNAL OF CLINICAL MEDICINE, 2021, 10 (10)
  • [10] Linezolid-based Regimens for Multidrug-resistant Tuberculosis (TB): A Systematic Review to Establish or Revise the Current Recommended Dose for TB Treatment
    Bolhuis, Mathieu S.
    Akkerman, Onno W.
    Sturkenboom, Marieke G. G.
    Ghimire, Samiksha
    Srivastava, Shashikant
    Gumbo, Tawanda
    Alffenaar, Jan-Willem C.
    [J]. CLINICAL INFECTIOUS DISEASES, 2018, 67 : S327 - S335